- Home
- EXFY vs BMEA Comparison
EXFY vs BMEA Comparison
Compare EXFY & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- BMEA
- Stock Information
- Founded
- EXFY 2008
- BMEA 2017
- Country
- EXFY United States
- BMEA United States
- Employees
- EXFY N/A
- BMEA N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- BMEA Health Care
- Exchange
- EXFY Nasdaq
- BMEA Nasdaq
- Market Cap
- EXFY 241.7M
- BMEA 275.6M
- IPO Year
- EXFY 2021
- BMEA 2021
- Fundamental
- Price
- EXFY $3.32
- BMEA $6.38
- Analyst Decision
- EXFY Buy
- BMEA Buy
- Analyst Count
- EXFY 4
- BMEA 13
- Target Price
- EXFY $2.83
- BMEA $37.25
- AVG Volume (30 Days)
- EXFY 786.0K
- BMEA 814.9K
- Earning Date
- EXFY 11-07-2024
- BMEA 10-29-2024
- Dividend Yield
- EXFY N/A
- BMEA N/A
- EPS Growth
- EXFY N/A
- BMEA N/A
- EPS
- EXFY N/A
- BMEA N/A
- Revenue
- EXFY $137,440,000.00
- BMEA N/A
- Revenue This Year
- EXFY N/A
- BMEA N/A
- Revenue Next Year
- EXFY $7.39
- BMEA N/A
- P/E Ratio
- EXFY N/A
- BMEA N/A
- Revenue Growth
- EXFY N/A
- BMEA N/A
- 52 Week Low
- EXFY $1.24
- BMEA $3.61
- 52 Week High
- EXFY $3.34
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- EXFY 80.91
- BMEA 24.23
- Support Level
- EXFY $2.63
- BMEA $6.04
- Resistance Level
- EXFY $2.97
- BMEA $9.34
- Average True Range (ATR)
- EXFY 0.22
- BMEA 0.54
- MACD
- EXFY 0.10
- BMEA -0.26
- Stochastic Oscillator
- EXFY 99.01
- BMEA 10.30
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.